- Zacks•8 hours ago
AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.
- Investor's Business Daily•yesterday
The FDA's track record for oncology "hits" bodes well for Merck's Keytruda plus chemo combo, Leerink says.
- Financial Times•yesterday
Anglo-Swedish drugmaker AstraZeneca is expanding its widely watched trials for durvalumab, a potential breakthrough treatment for several forms of cancer. The drug is among a group of therapies designed ...
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,500.00 x 6100|
|Ask||4,615.00 x 13000|
|Day's Range||4,544.00 - 4,600.00|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||23.50|
|Dividend & Yield||2.80 (4.97%)|
|1y Target Est||N/A|